Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.

[1]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[2]  B. Rovin,et al.  Tolerating Increases in the Serum Creatinine following Aggressive Treatment of Chronic Kidney Disease, Hypertension and Proteinuria: Pre-Renal Success , 2012, American Journal of Nephrology.

[3]  G. Remuzzi,et al.  Dealing with Renin-Angiotensin Inhibitors, Don’t Mind Serum Creatinine , 2012, American Journal of Nephrology.

[4]  Keith C. Norris,et al.  Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). , 2012, Archives of internal medicine.

[5]  D. Grobbee,et al.  Relation Between Blood Pressure and Vascular Events and Mortality in Patients With Manifest Vascular Disease: J-Curve Revisited , 2012, Hypertension.

[6]  S. Yusuf,et al.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). , 2012, Journal of the American College of Cardiology.

[7]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[8]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[9]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[10]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[11]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[12]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[13]  S. Nesbitt,et al.  Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk , 2007, Blood pressure.

[14]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[15]  G. Bakris,et al.  Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. , 2004, American journal of hypertension.

[16]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[17]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[18]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[19]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[20]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[21]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[22]  G. Bakris,et al.  SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach , 2000 .

[23]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[24]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[25]  C. Lenfant,et al.  National High Blood Pressure Education Program. , 1986, Journal of the American Optometric Association.